Deal expands company’s arrangement with RCUK.

Sigma Life Science signed a three-year contract with Research Councils UK (RCUK) Shared Services Centre to be a prefered supplier for synthetic oligonucleotides. With more than 20 years of experience in oligonucleotide synthesis, the company offers a broad, commercially available range of high-quality oligonucleotide modifications, purifications, synthesis scales, and qPCR probes. It has a U.K. production facility in Haverhill, near Cambridge.

“Sigma Life Science has been a preferred oligonucleotide supplier to the Medical Research Council (one of the U.K.’s seven Research Councils) for over four years,” notes Michael Harris, managing director of Europe, Middle East, and Africa regions for Sigma-Aldrich. “This new agreement is expected to enable additional RCUK researchers to access Sigma’s products as well as allow Sigma Life Science to consolidate its relationship with RCUK.”

Sigma Life Science provides a range of other molecular biology reagents including nucleic acid amplification and purification reagents, RNAi products like shRNAs, siRNAs, and ZFN technology, as well as more than 38,000 antibodies.

Previous articleGenmab Taps into Seattle’s ADC Technology to Develop Anticancer HuMax-TF Conjugate
Next articleIcagen Stops Epilepsy Trial with Ion-Channel Drug after Serious Adverse Event